
Wednesday, June 17, 2020 2:36:12 PM
Looking solid today
GO $ARYAW

Liked By
Spread the love. Be the first to like this post!
Recent NAUT News
- Nautilus Biotechnology to Announce Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023 • GlobeNewswire Inc. • 01/26/2023 01:00:00 PM
- Nautilus Biotechnology Expands to San Diego • GlobeNewswire Inc. • 01/26/2023 12:45:00 PM
- Nautilus Biotechnology Partners with the Translational Genomics Research Institute (TGen) to Investigate Applications of Single-Molecule Proteomic Analysis in Diffuse Intrinsic Pontine Glioma (DIPG) • GlobeNewswire Inc. • 01/19/2023 01:00:00 PM
- Nautilus Biotechnology Launches “First Access Challenge” • GlobeNewswire Inc. • 11/16/2022 01:00:00 PM
- Quarterly Report (10-q) • Edgar (US Regulatory) • 11/01/2022 08:10:29 PM
- Amended Current Report Filing (8-k/a) • Edgar (US Regulatory) • 11/01/2022 10:10:26 AM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 11/01/2022 10:08:15 AM
- Nautilus Biotechnology Reports Third Quarter 2022 Financial Results • GlobeNewswire Inc. • 11/01/2022 10:05:00 AM
- Nautilus Biotechnology to Announce Third Quarter 2022 Financial Results on November 1, 2022 • GlobeNewswire Inc. • 10/05/2022 12:00:00 PM
- Nautilus Biotechnology to Participate in the Capital One Spatial Biology & Proteomics Summit • GlobeNewswire Inc. • 09/23/2022 12:00:00 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 09/19/2022 09:51:02 PM
- Nautilus Biotechnology Joins Human Proteome Organization (HUPO) Industrial Advisory Board • GlobeNewswire Inc. • 09/01/2022 12:00:00 PM
- Nautilus Biotechnology to Participate in the Morgan Stanley Global Healthcare Conference • GlobeNewswire Inc. • 08/30/2022 12:00:00 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 08/22/2022 11:41:33 PM
- Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) • Edgar (US Regulatory) • 08/09/2022 08:23:22 PM
- Notice of Effectiveness (effect) • Edgar (US Regulatory) • 08/09/2022 10:08:45 AM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 08/08/2022 11:49:38 PM
- Nautilus Biotechnolgy (NAUT) Gets a Hold Rating from Goldman Sachs • TipRanks • 08/03/2022 04:45:09 PM
- Nautilus Biotechnolgy (NAUT) Gets a Hold Rating from Morgan Stanley • TipRanks • 08/03/2022 04:44:51 PM
- Post-effective Amendment to Registration Statement (pos Am) • Edgar (US Regulatory) • 08/02/2022 08:28:47 PM
- Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) • Edgar (US Regulatory) • 08/02/2022 08:25:46 PM
- Quarterly Report (10-q) • Edgar (US Regulatory) • 08/02/2022 08:05:41 PM
- Nautilus Biotechnology Reports Second Quarter 2022 Financial Results • GlobeNewswire Inc. • 08/02/2022 10:48:06 AM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 08/02/2022 10:00:58 AM
- Nautilus Biotechnology Appoints Eric Spence as Vice President of Instrument Engineering and Ken Kuhn, Ph.D., as Vice President of Reagent and Platform Development • GlobeNewswire Inc. • 08/01/2022 08:05:00 PM
1606 Corp Now Trading under Ticker CBDW, Management Announces First Acquisition • CBDW • Jan 27, 2023 11:59 AM
IQST - iQSTEL Reminds Shareholders To Get Their Votes In Before Annual Meeting Next Week On January 31, 2023 • IQST • Jan 26, 2023 9:53 AM
Nextech AR's AI-Powered CAD to Poly Toggle3D Launches Major Technology Advancements • ARWYF • Jan 26, 2023 8:46 AM
UCASU jump-starts its plan of NASDAQ or NYSE up-listing in 2023 • UCASU • Jan 26, 2023 7:21 AM
Kaya Holdings, Inc. (OTCQB: KAYS) Launches Fifth Dimension Therapeutics™ to seek to Provide Innovative Psychedelic-Based Treatments for Depression and Anxiety Related Conditions and Address the Growing Multi-Billion Dollar Global Psychedelics Market • KAYS • Jan 25, 2023 10:53 AM
B2 Digital's B2 SPORTS NETWORK (B2SN) Expands Distribution to Europe, Russia, and Asia with StayLIVE Agreement • BTDG • Jan 25, 2023 10:00 AM